Citations (106)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (17)
Burhan Ferhanoglu & Murat Ozbalak. (2023) Sequencing novel agents in the treatment of classical Hodgkin lymphoma. Expert Review of Hematology 0:0, pages 1-25.
Read now
Read now
Farheen Manji, Rob C Laister & John Kuruvilla. (2022) An evaluation of pembrolizumab for classical Hodgkin lymphoma. Expert Review of Hematology 15:4, pages 285-293.
Read now
Read now
Harsh Shah, Hyejeong Jang, Paramveer Singh, Jorgena Kosti, Andrew Kin, Asif Alavi, Voravit Ratanatharathorn, Lois Ayash, Joseph Uberti, Radhakrishnan Ramchandren, Seongho Kim & Abhinav Deol. (2022) Improved post-ASCT survival of relapsed/refractory classical Hodgkin lymphoma patients in the era of novel agents. Leukemia & Lymphoma 63:4, pages 813-820.
Read now
Read now
Shinichi Makita, Dai Maruyama & Kensei Tobinai. (2020) Safety and Efficacy of Brentuximab Vedotin in the Treatment of Classic Hodgkin Lymphoma. OncoTargets and Therapy 13, pages 5993-6009.
Read now
Read now
Ahmed Sawas, Helen Ma, John Kuruvilla, Jennifer K. Lue, Changchun Deng, Enrica Marchi, Francesca Montanari, Bin Cheng, Kerry J. Savage, Diego Villa, Michael Crump, Joseph M. Connors & Owen A. O’Connor. (2020) Prolonged progression free survival in a subset of responders to the combination of brentuximab vedotin and bendamustine in heavily treated patients with relapsed or refractory Hodgkin lymphoma: updated results from an international multi-center phase I/II experience. Leukemia & Lymphoma 61:12, pages 3014-3017.
Read now
Read now
Kirill V. Lepik, Natalia B. Mikhailova, Ivan S. Moiseev, Elena V. Kondakova, Luibov A. Tsvetkova, Yuri R. Zalyalov, Evgeniya S. Borzenkova, Elena V. Babenko, Vadim V. Baykov, Inna V. Markova & Boris V. Afanasyev. (2019) Nivolumab for the treatment of relapsed and refractory classical Hodgkin lymphoma after ASCT and in ASCT-naïve patients. Leukemia & Lymphoma 60:9, pages 2316-2319.
Read now
Read now
Mayur Narkhede, Maryam Sarraf Yazdy & Bruce Cheson. (2018) Determining the sequence of novel therapies in the treatment of relapsed Hodgkin’s lymphoma. Expert Review of Hematology 11:10, pages 773-780.
Read now
Read now
Eva M Donato, Miguel Fernández-Zarzoso, Jose Antonio Hueso & Javier de la Rubia. (2018) Brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma: an evidence-based review. OncoTargets and Therapy 11, pages 4583-4590.
Read now
Read now
Sam Keeping, Elise Wu, Keith Chan, Ali Mojebi, Shannon Allen Ferrante & Arun Balakumaran. (2018) Pembrolizumab versus the standard of care for relapsed and refractory classical Hodgkin’s lymphoma progressing after brentuximab vedotin: an indirect treatment comparison. Expert Review of Hematology 11:6, pages 503-511.
Read now
Read now
Erin A. Zagadailov, Shelby Corman, Viktor Chirikov, Courtney Johnson, Cynthia Macahilig, Brian Seal, Mehul R. Dalal, Paul J. Bröckelmann & Tim Illidge. (2018) Real-world effectiveness of brentuximab vedotin versus physicians’ choice chemotherapy in patients with relapsed/refractory Hodgkin lymphoma following autologous stem cell transplantation in the United Kingdom and Germany. Leukemia & Lymphoma 59:6, pages 1413-1419.
Read now
Read now
Dennis A. Eichenauer & Andreas Engert. (2017) The evolving role of targeted drugs in the treatment of Hodgkin lymphoma. Expert Review of Hematology 10:9, pages 775-782.
Read now
Read now
Christopher Parker, Beth Woods, James Eaton, Esprit Ma, Ross Selby, Eugene Benson, Andreas Engstrom, Peter Sajosi, Andrew Briggs & Vijayveer Bonthapally. (2017) Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous stem cell transplant: a cost-effectiveness analysis in Scotland. Journal of Medical Economics 20:1, pages 8-18.
Read now
Read now
Bastian von Tresckow, Franck Morschhauser, Jeffrey Szer, Dennis A. Eichenauer, Jeremy S. Abramson, Anna Sureda & Andreas Engert. (2017) Panobinostat consolidation in patients with Hodgkin lymphoma at risk for relapse after high dose chemotherapy and autologous stem cell transplant: final results after early trial discontinuation. Leukemia & Lymphoma 58:1, pages 222-225.
Read now
Read now
Paul J. Bröckelmann, Peter Borchmann & Andreas Engert. (2016) Current and future immunotherapeutic approaches in Hodgkin lymphoma. Leukemia & Lymphoma 57:9, pages 2014-2024.
Read now
Read now
Eunhye Oak & Nancy L. Bartlett. (2016) A safety evaluation of brentuximab vedotin for the treatment of Hodgkin lymphoma. Expert Opinion on Drug Safety 15:6, pages 875-882.
Read now
Read now
Árpád Illés, Ádám Jóna & Zsófia Miltényi. (2015) Brentuximab vedotin for treating Hodgkin’s lymphoma: an analysis of pharmacology and clinical efficacy. Expert Opinion on Drug Metabolism & Toxicology 11:3, pages 451-459.
Read now
Read now
Bastian von Tresckow, Horst Müller, Dennis A. Eichenauer, Jan P. Glossmann, Andreas Josting, Boris Böll, Beate Klimm, Stephanie Sasse, Michael Fuchs, Peter Borchmann & Andreas Engert. (2014) Outcome and risk factors of patients with Hodgkin Lymphoma who relapse or progress after autologous stem cell transplant. Leukemia & Lymphoma 55:8, pages 1922-1924.
Read now
Read now
Articles from other publishers (89)
TAHA al-juhaishi & SAIRAH ahmed. 2024. Manual of Hematopoietic Cell Transplantation and Cellular Therapies. Manual of Hematopoietic Cell Transplantation and Cellular Therapies
357
370
.
Sanjal H. Desai, Michael A Spinner, Andrew M. Evens, Alice Sykorova, Veronika Bachanova, Gaurav Goyal, Brad Kahl, Kathleen Dorritie, Jacues Azzi, Vaishalee P. Kenkre, Cheryl Chang, Jozef Michalka, Stephen M. Ansell, Brendon Fusco, Nuttavut Sumransub, Haris Hatic, Raya Saba, Uroosa Ibrahim, Elyse I. Harris, Harsh Shah, Nina Wagner-Johnston, Sally Arai, Grzegorz S. Nowakowski, Heidi Mocikova, Deepa Jagadeesh, Kristie A. Blum, Catherine Diefenbach, Siddharth Iyengar, K. C. Rappazzo, Firas Baidoun, Yun Choi, Vit Prochazka, Ranjana H. Advani & Ivana Micallef. (2023) Overall survival of patients with cHL who progress after autologous stem cell transplant: results in the novel agent era. Blood Advances 7:23, pages 7295-7303.
Crossref
Crossref
Michael P. Randall & Michael A. Spinner. (2023) Optimizing Treatment for Relapsed/Refractory Classic Hodgkin Lymphoma in the Era of Immunotherapy. Cancers 15:18, pages 4509.
Crossref
Crossref
Natacha Rodrigues, Mariana Fragão-Marques, Cláudia Costa, Carolina Branco, Filipe Marques, Pedro Vasconcelos, Carlos Martins, Adelino Leite-Moreira & José António Lopes. (2023) Predictive Risk Score for Acute Kidney Injury in Hematopoietic Stem Cell Transplant. Cancers 15:14, pages 3720.
Crossref
Crossref
Faryal Munir, Viney Hardit, Irtiza N. Sheikh, Shaikha AlQahtani, Jiasen He, Branko Cuglievan, Chitra Hosing, Priti Tewari & Sajad Khazal. (2023) Classical Hodgkin Lymphoma: From Past to Future—A Comprehensive Review of Pathophysiology and Therapeutic Advances. International Journal of Molecular Sciences 24:12, pages 10095.
Crossref
Crossref
Fauzia Ullah, Danai Dima, Najiullah Omar, Olisaemeka Ogbue & Sairah Ahmed. (2023) Advances in the treatment of Hodgkin lymphoma: Current and future approaches. Frontiers in Oncology 13.
Crossref
Crossref
Vittorio Stefoni, Lisa Argnani, Matteo Carella, Beatrice Casadei, Alice Morigi, Ginevra Lolli, Alessandro Broccoli, Cinzia Pellegrini, Laura Nanni, Paolo Elia Coppola & Pier Luigi Zinzani. (2022) BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma: a real-life experience. Journal of Cancer Research and Clinical Oncology 149:3, pages 1043-1047.
Crossref
Crossref
Aung M. Tun, Yucai Wang, Aasiya Matin, David J. Inwards, Thomas M. Habermann, Ivana Micallef, Patrick B. Johnston, Luis Porrata, Jonas Paludo, Jose Villasboas Bisneto, Allison Rosenthal, Han W. Tun, James R. Cerhan, Thomas E. Witzig, Grzegorz S. Nowakowski & Stephen M. Ansell. (2023) Outcomes of Patients With Classic Hodgkin Lymphoma Who Relapsed After Autologous Stem Cell Transplant. HemaSphere 7:4, pages e869.
Crossref
Crossref
Xiao-Yin Zhang & Graham P. Collins. (2022) Checkpoint Inhibitors and the Changing Face of the Relapsed/Refractory Classical Hodgkin Lymphoma Pathway. Current Oncology Reports 24:11, pages 1477-1488.
Crossref
Crossref
Alnecia R Nisbett, Xiaoqin Yang, Patrick Squires, Santosh Gautam, Kaushal Desai, Monika Raut & Akash Nahar. (2022) Treatment patterns and clinical outcomes among patients with relapsed/refractory classical Hodgkin's lymphoma. Future Oncology 18:32, pages 3623-3636.
Crossref
Crossref
Ezel ELGUN, Vildan GÜRSOY, Tuba ERSAL, İbrahim Ethem PINAR, Fahir ÖZKALEMKAŞ & Vildan OZKOCAMAN. (2022) Relaps/Refrakter Hodgkin Lenfoma Hastalarının Otolog Hematopoetik Kök Hücre Nakil Sonuçları ve Risk Faktörü Etkilerinin Retrospektif DeğerlendirilmesiRetrospective Evaluation of the Results of Autologous Hematopoietic Stem Cell Transplantation and the Effects of Risk Factors in Patients With Relaps/Refractory Hodgkin Lymphoma. Uludağ Üniversitesi Tıp Fakültesi Dergisi 48:2, pages 231-237.
Crossref
Crossref
Anastasia Beynarovich, Kirill Lepik, Natalia Mikhailova, Evgenia Borzenkova, Nikita Volkov, Ivan Moiseev, Yuri Zalyalov, Elena Kondakova, Andrey Kozlov, Lilia Stelmakh, Olga Pirogova, Lyudmila Zubarovskaya, Alexander Kulagin & Boris Afanasyev. (2022) Favorable outcomes of allogeneic hematopoietic stem cell transplantation with fludarabine–bendamustine conditioning and posttransplantation cyclophosphamide in classical Hodgkin lymphoma. International Journal of Hematology 116:3, pages 401-410.
Crossref
Crossref
Radhika Takiar & Yasmin Karimi. (2022) Novel Salvage Therapy Options for Initial Treatment of Relapsed/Refractory Classical Hodgkin’s Lymphoma: So Many Options, How to Choose?. Cancers 14:14, pages 3526.
Crossref
Crossref
Yuqin Song, Keshu Zhou, Chuan Jin, Zhengzi Qian, Ming Hou, Lei Fan, Fei Li, Kaiyang Ding, Hui Zhou, Xiaoling Li, Bing Chen, Xiuhua Sun, Xianmin Song, Ming Jiang, Qingyuan Zhang, Lihong Liu, Guohua Yu, Yu Hu, Zheng Zhao, Ligen Liu, Hongwei Xue, Jun Luo, Bai He, Xiaoping Jin, Min Zhao, Baiyong Li, Yu Xia & Jun Zhu. (2022) Penpulimab for Relapsed or Refractory Classical Hodgkin Lymphoma: A Multicenter, Single-Arm, Pivotal Phase I/II Trial (AK105-201). Frontiers in Oncology 12.
Crossref
Crossref
John Kuruvilla. (2022) Immunotherapy in Hodgkin lymphoma. Canadian Hematology Today.
Crossref
Crossref
Ali Bazarbachi, Ariane Boumendil, Hervé Finel, Irma Khvedelidze, Joanna Romejko-Jarosinska, Alina Tanase, Saad Akhtar, Tarek Ben Othman, Mohammad Ma’koseh, Boris Afanasyev, Jean Cheikh, Javier Briones, Zafer Gülbas, Rose-Marie Hamladji, Tugrul Elverdi, Didier Blaise, Carmen Martínez, Eleonora Alma, Kazimierz Halaburda, Aida Botelho Sousa, Bertram Glass, Steven Robinson, Silvia Montoto & Anna Sureda. (2022) The outcome of patients with Hodgkin lymphoma and early relapse after autologous stem cell transplant has improved in recent years. Leukemia 36:6, pages 1646-1653.
Crossref
Crossref
Ho‐Young Yhim, Yael Eshet, Ur Metser, Katherine Lajkosz, Matthew Cooper, Anca Prica, Vishal Kukreti, Sita Bhella, Noémie Lang, Wei Xu, Danielle Rodin, David Hodgson, Richard Tsang, Michael Crump, John Kuruvilla & Robert Kridel. (2022) Risk stratification for relapsed/refractory classical Hodgkin lymphoma integrating pretransplant Deauville score and residual metabolic tumor volume. American Journal of Hematology 97:5, pages 583-591.
Crossref
Crossref
Paul J. Bröckelmann, Horst Müller, Sarah Gillessen, Xiaoqin Yang, Larissa Koeppel, Veronika Pilz, Patricia Marinello, Peter Kaskel, Monika Raut, Michael Fuchs, Peter Borchmann, Andreas Engert & Bastian von Tresckow. (2021) Clinical outcomes of relapsed and refractory Hodgkin lymphoma patients after contemporary first-line treatment: a German Hodgkin Study Group analysis. Leukemia 36:3, pages 772-780.
Crossref
Crossref
Taha Al-Juhaishi, Azra Borogovac, Sami Ibrahimi, Matthew Wieduwilt & Sairah Ahmed. (2022) Reappraising the Role of Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed and Refractory Hodgkin’s Lymphoma: Recent Advances and Outcomes. Journal of Personalized Medicine 12:2, pages 125.
Crossref
Crossref
Artem Gusak, Liudmila Fedorova, Kirill Lepik, Nikita Volkov, Marina Popova, Ivan Moiseev, Natalia Mikhailova, Vadim Baykov & Alexander Kulagin. (2021) Immunosuppressive Microenvironment and Efficacy of PD-1 Inhibitors in Relapsed/Refractory Classic Hodgkin Lymphoma: Checkpoint Molecules Landscape and Macrophage Populations. Cancers 13:22, pages 5676.
Crossref
Crossref
Olga Meltem Akay, Murat Ozbalak, Mustafa Pehlivan, Birol Yildiz, Ant Uzay, Tugce Nur Yigenoglu, Tugrul Elverdi, Leylagul Kaynar, Orhan Ayyildiz, Ipek Yonal Hindilerden, Hasan Sami Goksoy, Sebnem Izmir Guner, Ahmet Kursad Gunes, Mehmet Sonmez, Meltem Kurt Yuksel, Sinem Civriz Bozdag, Zubeyde Nur Ozkurt, Tayfur Toptas, Mehmet Hilmi Dogu, Ozan Salim, Guray Saydam, Irfan Yavasoglu, Meltem Ayli, Gulsum Ozet, Murat Albayrak, Elif Birtas Atesoglu, Selami K. Toprak, Rahsan Yildirim, Ozgur Mehtap, Sevgi Kalayoglu Besisik, Meliha Nalcaci, Fevzi Altuntas & Burhan Ferhanoglu. (2021) Brentuximab vedotin consolidation therapy after autologous stem‐cell transplantation in patients with high‐risk Hodgkin lymphoma: Multicenter retrospective study. Hematological Oncology 39:4, pages 498-505.
Crossref
Crossref
Gian Luca Breschi, Federica Demma, Paolo Morelli & Maria De Francesco. (2021) Brentuximab vedotin in adult patients with HL CD30+ at high risk of relapse or progression following ASCT: a cost-analysis in Italy. AboutOpen 8:1, pages 81-87.
Crossref
Crossref
John Kuruvilla, Radhakrishnan Ramchandren, Armando Santoro, Ewa Paszkiewicz-Kozik, Robin Gasiorowski, Nathalie A Johnson, Laura Maria Fogliatto, Iara Goncalves, Jose S R de Oliveira, Valeria Buccheri, Guilherme F Perini, Neta Goldschmidt, Iryna Kriachok, Michael Dickinson, Mieczyslaw Komarnicki, Andrew McDonald, Muhit Ozcan, Naohiro Sekiguchi, Ying Zhu, Akash Nahar, Patricia Marinello & Pier Luigi Zinzani. (2021) Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study. The Lancet Oncology 22:4, pages 512-524.
Crossref
Crossref
Leyre Bento, Ariane Boumendil, Hervé Finel, Irma Khvedelidze, Didier Blaise, Nathalie Fegueux, Luca Castagna, Edouard Forcade, Patrice Chevallier, Nicola Mordini, Pauline Brice, Eric Deconinck, Martin Gramatzki, Paolo Corradini, Mathilde Hunault, Maurizio Musso, Anna Tsoulkani, Dolores Caballero, Sandro Nati, Silvia Montoto & Anna Sureda. (2020) Tandem autologous-reduced intensity allogeneic stem cell transplantation in high-risk relapsed Hodgkin lymphoma: a retrospective study of the Lymphoma Working Party—EBMT. Bone Marrow Transplantation 56:3, pages 655-663.
Crossref
Crossref
Nancy L. BartlettAlex F. HerreraEva Domingo-Domenech, Amitkumar Mehta, Andres Forero-TorresRamon Garcia-Sanz, Philippe ArmandSumana DevataAntonia Rodriguez IzquierdoIzidore S. Lossos, Craig ReederTaimur SherRobert ChenSylvia E. SchwarzLeila Alland, Andras StrasszKim PrierCassandra Choe-Juliak & Stephen M. Ansell. (2020) A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma. Blood 136:21, pages 2401-2409.
Crossref
Crossref
Weiwei Xu & Jing Wu. (2020) International experience with performance-based risk-sharing arrangements: implications for the Chinese innovative pharmaceutical market. International Journal of Technology Assessment in Health Care 36:5, pages 486-491.
Crossref
Crossref
Talha Badar, John Astle, Imran K. Kakar, Katie Zellner, Parameswaran N. Hari & Mehdi Hamadani. (2020) Clinical activity of ibrutinib in classical Hodgkin lymphoma relapsing after allogeneic stem cell transplantation is independent of tumor BTK expression. British Journal of Haematology 190:2.
Crossref
Crossref
Kirill V. Lepik, Natalia B. Mikhailova, Elena V. Kondakova, Yuri R. Zalyalov, Liudmila V. Fedorova, Luibov A. Tsvetkova, Polina V. Kotselyabina, Evgeniya S. Borzenkova, Elena V. Babenko, Marina O. Popova, Elena I. Darskaya, Vadim V. Baykov, Ivan S. Moiseev & Boris V. Afanasyev. (2020) A Study of Safety and Efficacy of Nivolumab and Bendamustine (NB) in Patients With Relapsed/Refractory Hodgkin Lymphoma After Nivolumab Monotherapy Failure. HemaSphere 4:3, pages e401.
Crossref
Crossref
Madiha Iqbal & Mohamed A. Kharfan-Dabaja. (2020) Relapse of Hodgkin lymphoma after autologous hematopoietic cell transplantation: A current management perspective. Hematology/Oncology and Stem Cell Therapy.
Crossref
Crossref
A S Kolbin, I A Vilyum, M A Proskurin, Yu E Balikina & A V Pavlysh. (2020) Pharmacoeconomic analysis of atezolizumab plus nab-paclitaxel in the treatment of the advanced or metastatic triple-negative breast cancer. Kachestvennaya klinicheskaya praktika:1, pages 4-21.
Crossref
Crossref
Marie José Kersten, Julia Driessen, Josée M. Zijlstra, Wouter J. Plattel, Franck Morschhauser, Pieternella J. Lugtenburg, Pauline Brice, Martin Hutchings, Thomas Gastinne, Roberto Liu, Coreline N. Burggraaff, Marcel Nijland, Sanne H. Tonino, Anne I.J. Arens, Roelf Valkema, Harm van Tinteren, Marta Lopez-Yurda, Arjan Diepstra, Daphne De Jong & Anton Hagenbeek. (2020) Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study. Haematologica 106:4, pages 1129-1137.
Crossref
Crossref
Panayotis Kaloyannidis, Mark Hertzberg, Kate Webb, Athanasios Zomas, Rudolf Schrover, Michael Hurst, Ian Jacob, Thalia Nikoglou & Joseph M. Connors. (2019) Brentuximab vedotin for the treatment of patients with relapsed or refractory Hodgkin lymphoma after autologous stem cell transplantation. British Journal of Haematology 188:4, pages 540-549.
Crossref
Crossref
Talha Badar, Narendranath Epperla, Aniko Szabo, Steven Borson, John VaughnGemlyn GeorgeNeeraj Saini, Abdul Rashid Shah, Romil D. Patel, Sairah Ahmed, Nirav N. ShahAmanda F. Cashen, Mehdi Hamadani & Timothy S. Fenske. (2020) Trends in postrelapse survival in classic Hodgkin lymphoma patients after experiencing therapy failure following auto-HCT. Blood Advances 4:1, pages 47-54.
Crossref
Crossref
Jelena Cakić & Irena Đunić. (2020) Therapeutic response in patients with CD30+ lymphomas to biological therapy. Medicinski podmladak 71:4, pages 63-68.
Crossref
Crossref
K.V. Lepik, N.P. Volkov, N.B. Mikhailova, E.V. Kondakova, L.A. Tsvetkova, Yu.R. Zalyalov, Ye.Ye. Lepik, L.V. Fedorova, A.V. Beinarovich, M.V. Demchenkova, O.G. Smykova, P.V. Kotselyabina, I.S. Moiseev, V.V. Baikov & B.V. Afanasyev. (2020) Long-Term Outcomes of Nivolumab Therapy in Patients with Relapsed/Refractory Classic Hodgkin’s Lymphoma after High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Transplantation in Real Clinical Practice. Clinical oncohematology 13:3, pages 280-288.
Crossref
Crossref
Yun Choi & Catherine S. Diefenbach. (2020) Advances in Therapy for Relapsed or Refractory Hodgkin Lymphoma. Current Oncology Reports 22:1.
Crossref
Crossref
Paul J. Bröckelmann & Lena Specht. 2020. Hodgkin Lymphoma. Hodgkin Lymphoma
145
169
.
A. Broccoli, L. Argnani, B. Botto, P. Corradini, A. Pinto, A. Re, U. Vitolo, S. Fanti, V. Stefoni & P. L. Zinzani. (2019) First salvage treatment with bendamustine and brentuximab vedotin in Hodgkin lymphoma: a phase 2 study of the Fondazione Italiana Linfomi. Blood Cancer Journal 9:12.
Crossref
Crossref
Sarah Gillessen & Bastian von Tresckow. (2019) Behandlung des refraktären/rezidivierten Hodgkin-Lymphoms. InFo Hämatologie + Onkologie 22:10, pages 16-20.
Crossref
Crossref
Guillaume Manson, Jean-Baptiste Mear, Charles Herbaux, Jean-Marc Schiano, Olivier Casasnovas, Aspasia Stamatoullas, Bénédicte Deau, Anna Schmitt, Georges Garnier, Caroline Regny, Krimo Bouabdallah, Marie-Pierre Moles-Moreau, Hervé Ghesquieres, Adrian Tempescul, Remy Dulery, Emmanuelle Nicolas-Virelizier, Alain Delmer, Cecile Borel, Adrien Chauchet, Diane Damotte, Laurent Dercle, Pauline Brice & Roch Houot. (2019) Long-term efficacy of anti-PD1 therapy in Hodgkin lymphoma with and without allogenic stem cell transplantation. European Journal of Cancer 115, pages 47-56.
Crossref
Crossref
Sachin R. Jhawar, Zorimar Rivera-Núñez, Richard Drachtman, Peter D. Cole, Bradford S. Hoppe & Rahul R. Parikh. (2019) Association of Combined Modality Therapy vs Chemotherapy Alone With Overall Survival in Early-Stage Pediatric Hodgkin Lymphoma. JAMA Oncology 5:5, pages 689.
Crossref
Crossref
Alessandro Broccoli & Pier Luigi Zinzani. (2019) The role of transplantation in Hodgkin lymphoma. British Journal of Haematology 184:1, pages 93-104.
Crossref
Crossref
Craig H. MoskowitzJan WalewskiAuayporn NademaneeTamas MassziEdward AguraJerzy HolowieckiMuneer H. AbidiAndy I. ChenPatrick StiffSimonetta VivianiVeronika BachanovaAnna SuredaTeresa McClendonConnie Lee, Julie LisanoJohn Sweetenham. (2018) Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse. Blood 132:25, pages 2639-2642.
Crossref
Crossref
Scott F. HuntingtonGottfried von KeudellAmy J. DavidoffCary P. GrossSapna A. Prasad. (2018) Cost-Effectiveness Analysis of Brentuximab Vedotin With Chemotherapy in Newly Diagnosed Stage III and IV Hodgkin Lymphoma. Journal of Clinical Oncology 36:33, pages 3307-3314.
Crossref
Crossref
M. Hutchings, M. Ladetto, C. Buske, P. de Nully Brown, A.J.M. Ferreri, M. Pfreundschuh, N. Schmitz, A. Sureda Balari, G. van Imhoff & J. Walewski. (2018) ESMO Consensus Conference on malignant lymphoma: management of ‘ultra-high-risk’ patients. Annals of Oncology 29:8, pages 1687-1700.
Crossref
Crossref
Charles HerbauxReid MerrymanSteven DevinePhilippe ArmandRoch Houot, Franck MorschhauserBradley Haverkos. (2018) Recommendations for managing PD-1 blockade in the context of allogeneic HCT in Hodgkin lymphoma: taming a necessary evil. Blood 132:1, pages 9-16.
Crossref
Crossref
Karl S. Peggs. (2018) Should all patients with Hodgkin lymphoma who relapse after autologous SCT be considered for allogeneic SCT?. Blood Advances 2:7, pages 817-820.
Crossref
Crossref
Louis S. Constine, Joachim Yahalom, Andrea K. Ng, David C. Hodgson, Andrew Wirth, Sarah A. Milgrom, N. George Mikhaeel, Hans Theodor Eich, Tim Illidge, Umberto Ricardi, Karin Dieckmann, Craig H. Moskowitz, Ranjana Advani, Peter M. Mauch, Lena Specht & Richard T. Hoppe. (2018) The Role of Radiation Therapy in Patients With Relapsed or Refractory Hodgkin Lymphoma: Guidelines From the International Lymphoma Radiation Oncology Group. International Journal of Radiation Oncology*Biology*Physics 100:5, pages 1100-1118.
Crossref
Crossref
Paul J. Bröckelmann, Bastian von Tresckow & Andreas Engert. (2018) Rezidiviertes oder refraktäres klassisches Hodgkin-LymphomRelapsed or refractory classical Hodgkin’s lymphoma. Der Onkologe 24:4, pages 322-328.
Crossref
Crossref
Elena Andreevna EA. (2018) PD-1 Blockade with Nivolumab as a New Immunotherapy for Classical Hodgkin’s Lymphoma. Clinical oncohematology 11:3, pages 213-219.
Crossref
Crossref
Kelley Ratermann, Jessica Cox, Lydia Benitez & Frank Davis. 2018. A Worldwide Yearly Survey of New Data in Adverse Drug Reactions. A Worldwide Yearly Survey of New Data in Adverse Drug Reactions
477
487
.
Raoudha Doghri, Maroua Manai, Pascal Finetti, Maha Driss, Emilie Agavnian, Marc Lopez, Meriam Elghardallou, Emmanuelle Charafe-Jauffret, Mohamed Manai, Max Chaffanet, Daniel Birnbaum, Karima Mrad & François Bertucci. (2017) Stromal Expression of MARCKS Protein in Ovarian Carcinomas Has Unfavorable Prognostic Value. International Journal of Molecular Sciences 19:1, pages 41.
Crossref
Crossref
E. A. Demina. (2017) TARGETED THERAPY WITH BRENTUXIMAB VEDOTIN IN RELAPSED AND REFRACTORY FORMS OF CLASSICAL HODGKIN LYMPHOMA. Medical Council:14, pages 88-92.
Crossref
Crossref
Yue Zhang, Juan Zhang, Hui Zeng, Xiao-Huan Zhou & He-Bing Zhou. (2017) Nomograms for predicting the overall and cancer-specific survival of patients with classical Hodgkin lymphoma: a SEER-based study. Oncotarget 8:54, pages 92978-92988.
Crossref
Crossref
Cinzia Pellegrini, Alessandro Broccoli, Alessandro Pulsoni, Luigi Rigacci, Caterina Patti, Guido Gini, Donato Mannina, Monica Tani, Chiara Rusconi, Alessandra Romano, Anna Vanazzi, Barbara Botto, Armando Santoro, Stefan Hoaus, Gian Matteo Rigolin, Pellegrino Musto, Patrizio Mazza, Stefano Molica, Paolo Corradini, Angelo Fama, Francesco Gaudio, Michele Merli, Fioravante Ronconi, Giuseppe Gritti, Daniele Vallisa, Patrizia Tosi, Anna Marina Liberati, Antonello Pinto, Vincenzo Pavone, Filippo Gherlinzoni, Maria Paola Bianchi, Stefano Volpetti, Livio Trentin, Maria Cecilia Goldaniga, Maurizio Bonfichi, Amalia De Renzo, Corrado Schiavotto, Michele Spina, Angelo Michele Carella, Vittorio Stefoni, Lisa Argnani & Pier Luigi Zinzani. (2017) Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin’s lymphoma. Oncotarget 8:53, pages 91703-91710.
Crossref
Crossref
Lucy Hui, Gottfried von Keudell, Rong Wang, Amer M. Zeidan, Steven D. Gore, Xiaomei Ma, Amy J. Davidoff & Scott F. Huntington. (2017) Cost-effectiveness analysis of consolidation with brentuximab vedotin for high-risk Hodgkin lymphoma after autologous stem cell transplantation. Cancer 123:19, pages 3763-3771.
Crossref
Crossref
Ruth Scheuvens. (2017) Immuntherapie beim Hodgkin-Lymphom. InFo Onkologie 20:S1, pages 36-42.
Crossref
Crossref
Steven M. Bair, Lauren Strelec, Sarah J. Nagle, Sunita D. Nasta, Daniel J. Landsburg, Anthony R. Mato, Alison W. Loren, Stephen J. Schuster, Edward A. Stadtmauer & Jakub Svoboda. (2017) Outcomes of patients with relapsed/refractory Hodgkin lymphoma progressing after autologous stem cell transplant in the current era of novel therapeutics: A retrospective analysis. American Journal of Hematology 92:9, pages 879-884.
Crossref
Crossref
Irene Biasoli & Nelson Spector. (2017) New agents in relapsed/refractory Hodgkin's lymphoma. Revista Brasileira de Hematologia e Hemoterapia 39:3, pages 193-196.
Crossref
Crossref
P.J. Bröckelmann, H. Müller, O. Casasnovas, M. Hutchings, B. von Tresckow, M. Jürgens, S.J. McCall, F. Morschhauser, M. Fuchs, P. Borchmann, C.H. Moskowitz & A. Engert. (2017) Risk factors and a prognostic score for survival after autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma. Annals of Oncology 28:6, pages 1352-1358.
Crossref
Crossref
L Hegerova, Q Cao, A Lazaryan, B L McClune, D J Weisdorf, C G Brunstein & V Bachanova. (2017) Improving outcomes after allogeneic hematopoietic cell transplantation for Hodgkin lymphoma in the brentuximab vedotin era. Bone Marrow Transplantation 52:5, pages 697-703.
Crossref
Crossref
Scott D. Ramsey, Auayporn Nademanee, Tamas Masszi, Jerzy Holowiecki, Muneer Abidi, Andy Chen, Patrick Stiff, Simonetta Viviani, John W. Sweetenham, John Radford, Yanyan Zhu, Vijayveer Bonthapally, Elizabeth Thomas, Akshara Richhariya, Naomi N. Hunder, Jan Walewski & Craig H. Moskowitz. (2016) Quality of life results from a phase 3 study of brentuximab vedotin consolidation following autologous haematopoietic stem cell transplant for persons with Hodgkin lymphoma. British Journal of Haematology 175:5, pages 860-867.
Crossref
Crossref
Gunjan L. Shah, Joachim Yahalom, Matthew J. Matasar, Stephanie L. Verwys, Debra A. Goldman, Kurt S. Bantilan, Zhigang Zhang, Susan J. McCall, Alison J. Moskowitz & Craig H. Moskowitz. (2016) Risk factors predicting outcomes for primary refractory hodgkin lymphoma patients treated with salvage chemotherapy and autologous stem cell transplantation. British Journal of Haematology 175:3, pages 440-447.
Crossref
Crossref
Robert ChenAjay K. GopalScott E. SmithStephen M. AnsellJoseph D. RosenblattKerry J. SavageJoseph M. ConnorsAndreas EngertEmily K. LarsenDirk Huebner, Abraham FongAnas Younes. (2016) Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood 128:12, pages 1562-1566.
Crossref
Crossref
Anas Younes, Armando Santoro, Margaret Shipp, Pier Luigi Zinzani, John M Timmerman, Stephen Ansell, Philippe Armand, Michelle Fanale, Voravit Ratanatharathorn, John Kuruvilla, Jonathon B Cohen, Graham Collins, Kerry J Savage, Marek Trneny, Kazunobu Kato, Benedetto Farsaci, Susan M Parker, Scott Rodig, Margaretha G M Roemer, Azra H Ligon & Andreas Engert. (2016) Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. The Lancet Oncology 17:9, pages 1283-1294.
Crossref
Crossref
Chan Y. Cheah, Paul J. Bröckelmann, Dai Chihara, Alison J. Moskowitz, Andreas Engert, Mats Jerkeman, Tarec C. El-Galaly, Bradley Augustson, Julie Vose, Nancy L. Bartlett, Diego Villa, Joseph M. Connors, Tatyana Feldman, Chelsea C. Pinnix, Sarah A. Milgrom, Bouthaina Dabaja, Yasuhiro Oki & Michelle A. Fanale. (2016) Clinical characteristics and outcomes of patients with Hodgkin lymphoma with central nervous system involvement: An international multicenter collaboration. American Journal of Hematology 91:9, pages 894-899.
Crossref
Crossref
Greg HapgoodYvonne ZhengLaurie H. SehnDiego VillaRichard KlasaAlina S. GerrieTamara ShenkierDavid W. ScottRandy D. GascoyneGraham W. SlackChristina ParsonsJames MorrisTom PicklesJoseph M. ConnorsKerry J. Savage. (2016) Evaluation of the Risk of Relapse in Classical Hodgkin Lymphoma at Event-Free Survival Time Points and Survival Comparison With the General Population in British Columbia. Journal of Clinical Oncology 34:21, pages 2493-2500.
Crossref
Crossref
C.Y. Cheah, D. Chihara, S. Horowitz, A. Sevin, Y. Oki, S. Zhou, N.H. Fowler, J.E. Romaguera, F. Turturro, F.B. Hagemeister, L.E. Fayad, M. Wang, S.S. Neelapu, L.J. Nastoupil, J.R. Westin, M.A. Rodriguez, F. Samaniego, P. Anderlini, Y. Nieto & M.A. Fanale. (2016) Patients with classical Hodgkin lymphoma experiencing disease progression after treatment with brentuximab vedotin have poor outcomes. Annals of Oncology 27:7, pages 1317-1323.
Crossref
Crossref
Peter Borchmann & Andreas Engert. (2016) Balancing the Risk-Benefit Ratio in the Treatment of Patients With Advanced-Stage Hodgkin Lymphoma. Journal of Clinical Oncology 34:17, pages 1975-1977.
Crossref
Crossref
Elena Andreevna Demina. (2016) Brentuximab Vedotin: New Possibilities for Treatment of Relapses and Refractory Hodgkin’s Lymphomas. Clinical oncohematology 9:4, pages 398-405.
Crossref
Crossref
Anas Younes. 2016. Handbook of Lymphoma. Handbook of Lymphoma
83
93
.
Catherine S. Diefenbach, Hailun Li, Fangxin Hong, Leo I. Gordon, Richard I. Fisher, Nancy L. Bartlett, Michael Crump, Randy D. Gascoyne, Henry WagnerJrJr, Patrick J. Stiff, Bruce D. Cheson, Douglas A. Stewart, Brad S. Kahl, Jonathan W. Friedberg, Kristie A. Blum, Thomas M. Habermann, Joseph M. Tuscano, Richard T. Hoppe, Sandra J. Horning & Ranjana H. Advani. (2015) Evaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for advanced Hodgkin lymphoma in the modern era. British Journal of Haematology 171:4, pages 530-538.
Crossref
Crossref
Rahul R. Parikh, Michael L. Grossbard, Louis B. Harrison & Joachim Yahalom. (2015) Early-Stage Classic Hodgkin Lymphoma: The?Utilization of Radiation Therapy and Its Impact on Overall Survival. International Journal of Radiation Oncology*Biology*Physics 93:3, pages 684-693.
Crossref
Crossref
Martin Hutchings, Miguel A. Piris, Otavio Baiocchi & Mark Hertzberg. (2015) Advances in the diagnosis and treatment of Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Cancer Treatment Communications 4, pages S1-S11.
Crossref
Crossref
Paul J. Bröckelmann & Andreas Engert. (2015) The GHSG Approach to Treating Hodgkin’s Lymphoma. Current Hematologic Malignancy Reports 10:3, pages 256-265.
Crossref
Crossref
Antonino Carbone, Annunziata Gloghini, Luca Castagna, Armando Santoro & Carmelo Carlo-Stella. (2015) Primary refractory and early-relapsed Hodgkin's lymphoma: strategies for therapeutic targeting based on the tumour microenvironment. The Journal of Pathology 237:1, pages 4-13.
Crossref
Crossref
Carmelo Carlo-Stella & Armando Santoro. (2015) Microenvironment-related biomarkers and novel targets in classical Hodgkin's lymphoma. Biomarkers in Medicine 9:8, pages 807-817.
Crossref
Crossref
Achim RotheStephanie Sasse, Max S. ToppDennis A. Eichenauer, Horst HummelKatrin S. ReinersMarkus Dietlein, Georg Kuhnert, Joerg KesslerCarolin Buerkle, Miroslav Ravic, Stefan Knackmuss, Jens-Peter Marschner, Elke Pogge von StrandmannPeter Borchmann & Andreas Engert. (2015) A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma. Blood 125:26, pages 4024-4031.
Crossref
Crossref
Andreas Engert. (2015) Hodgkin's lymphoma: who needs consolidation treatment?. The Lancet 385:9980, pages 1810-1812.
Crossref
Crossref
Craig H Moskowitz, Auayporn Nademanee, Tamas Masszi, Edward Agura, Jerzy Holowiecki, Muneer H Abidi, Andy I Chen, Patrick Stiff, Alessandro M Gianni, Angelo Carella, Dzhelil Osmanov, Veronika Bachanova, John Sweetenham, Anna Sureda, Dirk Huebner, Eric L Sievers, Andy Chi, Emily K Larsen, Naomi N Hunder & Jan Walewski. (2015) Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet 385:9980, pages 1853-1862.
Crossref
Crossref
Carmelo Carlo-StellaFrancesca RicciSerena DaltoRita MazzaMichele MalagolaFrancesca PatriarcaSimonetta Viviani, Domenico RussoLaura GiordanoLuca CastagnaPaolo CorradiniArmando Santoro. (2015) Brentuximab Vedotin in Patients With Hodgkin Lymphoma and a Failed Allogeneic Stem Cell Transplantation: Results From a Named Patient Program at Four Italian Centers. The Oncologist 20:3, pages 323-328.
Crossref
Crossref
Ajay K. GopalRobert ChenScott E. SmithStephen M. AnsellJoseph D. RosenblattKerry J. SavageJoseph M. ConnorsAndreas EngertEmily K. LarsenXuedong Chi, Eric L. SieversAnas Younes. (2015) Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. Blood 125:8, pages 1236-1243.
Crossref
Crossref
Phillip M. Garfin, Michael P. Link, Sarah S. Donaldson, Ranjana H. Advani, Sandra Luna-Fineman, Sandhya Kharbanda, Matthew Porteus, Kenneth I. Weinberg & Rajni Agarwal-Hashmi. (2015) Improved Outcomes after Autologous Bone Marrow Transplantation for Children with Relapsed or Refractory Hodgkin Lymphoma: Twenty Years Experience at a Single Institution. Biology of Blood and Marrow Transplantation 21:2, pages 326-334.
Crossref
Crossref
Stephen M. Ansell, Alexander M. Lesokhin, Ivan Borrello, Ahmad Halwani, Emma C. Scott, Martin Gutierrez, Stephen J. Schuster, Michael M. Millenson, Deepika Cattry, Gordon J. Freeman, Scott J. Rodig, Bjoern Chapuy, Azra H. Ligon, Lili Zhu, Joseph F. Grosso, Su Young Kim, John M. Timmerman, Margaret A. Shipp & Philippe Armand. (2015) PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma. New England Journal of Medicine 372:4, pages 311-319.
Crossref
Crossref
Robert Chen, Joycelynne M. Palmer, Ni-Chun Tsai, Sandra H. Thomas, Tanya Siddiqi, Leslie Popplewell, Len Farol, Auayporn Nademanee & Stephen J. Forman. (2014) Brentuximab Vedotin Is Associated with Improved Progression-Free Survival after Allogeneic Transplantation for Hodgkin Lymphoma. Biology of Blood and Marrow Transplantation 20:11, pages 1864-1868.
Crossref
Crossref
Dennis A. Eichenauer & Andreas Engert. (2014)
Antibodies and antibody‐drug conjugates in the treatment of
H
odgkin lymphoma
. European Journal of Haematology 93:1, pages 1-8.
Crossref
Crossref
Girish Venkataraman, M. Kamran Mirza, Dennis A. Eichenauer & Volker Diehl. (2014) Current status of prognostication in classical Hodgkin lymphoma. British Journal of Haematology 165:3, pages 287-299.
Crossref
Crossref
Catherine Diefenbach & Ranjana Advani. (2014) Customized Targeted Therapy in Hodgkin Lymphoma. Hematology/Oncology Clinics of North America 28:1, pages 105-122.
Crossref
Crossref
Mark Hertzberg. (2014) Relapsed/Refractory Hodgkin Lymphoma. Hematology/Oncology Clinics of North America 28:1, pages 123-147.
Crossref
Crossref